Collegium Pharmaceutical Inc. is a specialty pharmaceutical company. It develops and commercializes prescription and over-the-counter pharmaceuticals for the treatment of central nervous system, respiratory and skin related disorders. The Company's product candidate consists of COL-195, COL-196, COL-171, COL-003 and COL-172 which are in different clinical trial. It developed a formulation platform technology, DETERx, for the treatment of chronic pain. Collegium Pharmaceutical Inc. is based in CUMBERLAND, United States.
| Revenue (Most Recent Fiscal Year) | $566.77M |
| Net Income (Most Recent Fiscal Year) | $48.15M |
| PE Ratio (Current Year Earnings Estimate) | 5.11 |
| PE Ratio (Trailing 12 Months) | 5.04 |
| PEG Ratio (Long Term Growth Estimate) | -- |
| Price to Sales Ratio (Trailing 12 Months) | 1.54 |
| Price to Book Ratio (Most Recent Quarterly Book Value per Share) | 3.93 |
| Price to Cash Ratio (Most Recent Annual Cash Flow per Share) | 2.66 |
| Pre-Tax Margin (Trailing 12 Months) | 21.36% |
| Net Margin (Trailing 12 Months) | 14.78% |
| Return on Equity (Trailing 12 Months) | 104.67% |
| Return on Assets (Trailing 12 Months) | 18.38% |
| Current Ratio (Most Recent Fiscal Quarter) | 0.97 |
| Quick Ratio (Most Recent Fiscal Quarter) | 0.88 |
| Debt to Common Equity (Most Recent Fiscal Quarter) | 3.43 |
| Inventory Turnover (Trailing 12 Months) | 6.97 |
| Book Value per Share (Most Recent Fiscal Quarter) | $5.99 |
| Earnings per Share (Most Recent Fiscal Quarter) | $1.48 |
| Earnings per Share (Most Recent Fiscal Year) | $4.99 |
| Diluted Earnings per Share (Trailing 12 Months) | $2.32 |
| Exchange | NASDAQ |
| Sector | Healthcare |
| Industry | Drug Manufacturers - Specialty & Generic |
| Common Shares Outstanding | 32.25M |
| Free Float | 30.97M |
| Market Capitalization | $922.68M |
| Average Volume (Last 20 Days) | 0.45M |
| Beta (Past 60 Months) | 0.80 |
| Percentage Held By Insiders (Latest Annual Proxy Report) | 3.98% |
| Percentage Held By Institutions (Latest 13F Reports) | -- |
| Annual Dividend (Based on Last Quarter) | $0.00 |
| Dividend Yield (Based on Last Quarter) | 0.00% |